Clene(CLNN)
SALT LAKE CITY, UT
BiotechnologyFocus: Nanotherapeutics for neurological indications
Clene is a life sciences company focused on Nanotherapeutics for neurological indications.
Neurology
Funding Stage
PUBLIC
Employees
201-500
Open Jobs
0
Pipeline & Clinical Trials
CNM-Au8
ALSClinical Trials (1)
NCT06408727Intermediate Expanded Access Protocol CNMAu8.EAP04
N/AN/A
Clinical Trials (1)
NCT05281484Two Intermediate Expanded Access Protocols (EAP) CNMAu8.EAP01 and CNMAu8.EAP02 for ALS
N/ACNM-Au8
Multiple SclerosisClinical Trials (1)
NCT04081714Intermediate Expanded Access Protocol CNMAu8.EAP03
N/APhase 1
Clinical Trials (1)
NCT02755870A Phase I SAD and MAD Clinical Trial of CNM-Au8 in Healthy Male and Female Volunteers
Phase 1Phase 2
Clinical Trials (1)
NCT04098406Therapeutic Nanocatalysis to Slow Disease Progression of Amyotrophic Lateral Sclerosis (ALS)
Phase 2CNM-ZnAg
Covid19Clinical Trials (1)
NCT04610138Study of ZnAg Liquid Solution to Treat COVID-19 Symptomatic Participants
Phase 2gold nanocrystals
Multiple SclerosisClinical Trials (1)
NCT0399317131P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Multiple Sclerosis.
Phase 2Phase 2
Clinical Trials (1)
NCT05299658An Open-Label Extension for the Phase 2 Study in Early Symptomatic Amyotrophic Lateral Sclerosis Patients on Stable Background Therapy to Assess Bioenergetic Catalysis With CNM-Au8 to Slow Disease Progression in ALS
Phase 2Gold Nanocrystals
Amyotrophic Lateral SclerosisClinical Trials (1)
NCT0384371031P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Amyotrophic Lateral Sclerosis (REPAIR-ALS)
Phase 2Gold Nanocrystals
Parkinson's DiseaseClinical Trials (1)
NCT0381591631P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Parkinson's Disease
Phase 2Phase 2
Clinical Trials (1)
NCT03536559Nanocrystalline Gold to Treat Remyelination Failure in Chronic Optic Neuropathy In Multiple Sclerosis
Phase 2CNM-Au8
Relapsing Multiple SclerosisClinical Trials (1)
NCT04626921A Multi-Center, Open-Label Long-Term Extension Study of CNM-Au8 In Patients With Stable Relapsing Multiple Sclerosis
Phase 2/3Phase 2/3
Clinical Trials (1)
NCT04414345HEALEY ALS Platform Trial - Regimen C CNM-Au8
Phase 2/3Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Founded: 2013
Portfolio: 13 clinical trials
SEC Filings: 2 available
Financials (FY2024)
Revenue
$654K38%
R&D Spend
$27M(4076%)16%
Net Income
-$50MCash
$29M